Medicare Enrolled

Dr. Devesh Pandya, M.D.

Hematology & Oncology · Houston, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
2130 W HOLCOMBE BLVD, Houston, TX 77030
7136000900
In practice since 2008 (18 years)
NPI: 1770768210 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Pandya from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Pandya? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Pandya

Dr. Devesh Pandya is a hematology & oncology in Houston, TX, with 18 years in practice. Based on federal Medicare data, Dr. Pandya performed 38,784 Medicare services across 1,322 unique beneficiaries.

Between the years covered by Open Payments, Dr. Pandya received a total of $1,698,245 from 52 pharmaceutical and/or device companies across 1332 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Pandya is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice▲ Top 25% volume in TX$ $1,698,245 industry payments

Medicare Practice Summary

Medicare Utilization ↗
38,784
Medicare services
Top 25% in TX for hematology & oncology
1,322
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,155 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Iron infusion (Feraheme)25,500$0$2
Contrast dye for imaging (iodine-based)8,350$0$0
Dexamethasone injection (steroid)1,000$0$1
Anti-nausea injection (Aloxi/palonosetron)930$1$4
Complete blood count (CBC) with differential908$8$24
Office visit, established patient (30-39 min)371$90$393
Office visit, established patient, complex (40-54 min)181$132$557
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less151$22$90
Injection, zoledronic acid, 1 mg151$7$36
Administration of chemotherapy into vein, 1 hour or less135$99$414
Blood draw (venipuncture)122$8$10
Drug injection, under skin or into muscle119$11$51
Injection of additional new drug or substance into vein118$12$53
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less88$46$204
Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional82$16$72
Office visit, established patient (20-29 min)81$59$277
Blood test, basic group of blood chemicals (calcium, ionized)69$13$42
Ct scan of chest with contrast68$58$567
Blood creatinine level64$5$16
Administration of chemotherapy into vein, each additional hour63$19$89
Nuclear medicine study from skull base to mid-thigh with ct scan56$1,191$5,354
New patient office visit, complex (60-74 min)53$169$688
CT scan of abdomen and pelvis with contrast47$188$1,027
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries47$101$506
New patient office visit (45-59 min)30$120$519
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
66.4% high complexity
28.5% medium
5.2% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$1,698,245
Total received (2018-2024)
Avg $242,606/year across 7 years
Top 0% in TX for hematology & oncology
52
Companies
1,332
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,665,969 (98.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$29,687 (1.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,588 (0.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$429,518
2023
$330,814
2022
$253,079
2021
$131,336
2020
$109,980
2019
$192,502
2018
$251,015

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$584,900
GlaxoSmithKline, LLC.
$258,426
Gilead Sciences, Inc.
$153,294
Myriad Genetic Laboratories, Inc.
$117,310
Boehringer Ingelheim Pharmaceuticals, Inc.
$110,722
EMD Serono, Inc.
$74,925
JAZZ PHARMACEUTICALS INC.
$68,687
AstraZeneca Pharmaceuticals LP
$61,638
PFIZER INC.
$52,058
Amgen Inc.
$45,769
Karyopharm Therapeutics Inc.
$37,794
Janssen Pharmaceuticals, Inc
$30,999
Janssen Biotech, Inc.
$25,793
GENZYME CORPORATION
$18,419
Foundation Medicine, Inc.
$16,057
Helsinn Therapeutics (U.S.), Inc.
$9,008
Celgene Corporation
$8,262
Kite Pharma, Inc.
$4,945
Acceleron Pharma, Inc.
$4,495
Spectrum Pharmaceuticals Inc.
$2,663
Fresenius Kabi USA, LLC
$2,550
Astellas Pharma US Inc
$1,967
Ipsen Biopharmaceuticals, Inc
$1,741
Seattle Genetics, Inc.
$1,571
R-Pharm US LLC
$1,323
Janssen Scientific Affairs, LLC
$818
BeiGene USA, Inc.
$321
Novartis Pharmaceuticals Corporation
$280
Genentech USA, Inc.
$276
PUMA BIOTECHNOLOGY, INC.
$149
SpringWorks Therapeutics, Inc.
$146
Regeneron Healthcare Solutions, Inc.
$124
Stemline Therapeutics Inc.
$123
Lilly USA, LLC
$114
Daiichi Sankyo Inc.
$77
Bayer Healthcare Pharmaceuticals Inc.
$74
Sirtex Medical Inc
$71
Seagen Inc.
$43
Takeda Pharmaceuticals U.S.A., Inc.
$38
ARRAY BIOPHARMA INC
$37
Puma Biotechnology, Inc.
$25
TAIHO ONCOLOGY, INC.
$25
Exelixis Inc.
$24
Myriad Women's Health, Inc.
$23
Incyte Corporation
$20
PharmaEssentia USA Corporation
$19
EISAI INC.
$19
Pharming Healthcare, Inc.
$19
Verity Pharmaceuticals Inc.
$19
Taiho Oncology, Inc.
$18
Secura Bio, Inc.
$15
EUSA Pharma (US) LLC
$15
Top 3 companies account for 58.7% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AKYNZEO · ALOXI · AUGTYRO · BALVERSA · BAVENCIO · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABOMETYX · CHANTIX · CYRAMZA · DARZALEX · ELIQUIS · EMPLICITI · ENDOPREDICT · ENJAYMO · ERLEADA · EndoPredict · Enhertu · FOUNDATIONONE · FOUNDATIONONE LIQUID · Fabhalta · Farydak · Folotyn · GENESIGHT · GILOTRIF · IBRANCE · IMFINZI · IMJUDO · Ixempra · JEMPERLI · JEVTANA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MYCHOICE CDX · MYRISK · NERLYNX · NINLARO · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PRECISETUMOR · PROMACTA · Padcev · Pomalyst · PreciseTumor · REBLOZYL · RUCONEST · RYBREVANT · Reblozyl · SCEMBLIX · SIR-Spheres Microspheres · SUTENT · Sylvant · TECENTRIQ · Tazverik · Tecartus · Tecentriq · Trelstar · Trodelvy · VENCLEXTA · VERZENIO · Venclexta · XALKORI · XARELTO · XPOVIO · XTANDI · XYNTHA · Xospata · Yescarta · ZEJULA · ZEPZELCA · ZYKADIA · Zevalin · myChoice CDx · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (98%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for hematology & oncology in TX.

Equivalent to $4,379 per 100 Medicare services performed
Looking for a hematology & oncology in Houston?
Compare hematology & oncologys in the Houston area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncologys nearby

Geographic Context

Hematology & Oncologys within 10 mi
202
Per 100K population
4.2
County median income
$73,104
Nearest hospital
MEMORIAL HERMANN - TEXAS MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Pandya is a mixed practice specialist, with above-average Medicare volume (top 25% in TX), and high industry engagement (speaking/promotional, top 0%), with 18 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Pandya experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Pandya performed 25,500 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Pandya receive payments from pharmaceutical companies?
Yes. Dr. Pandya received a total of $1,698,245 from 52 companies across 1,332 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Pandya's costs compare to other hematology & oncologys in Houston?
Dr. Pandya's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Pandya) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →